ONCOLOGY Nurse Edition October 2008, Vol 22 No 11

Publication
Article
Oncology Nurse EditionONCOLOGY Nurse Edition Vol 22 No 11
Volume 22
Issue 11

October 2008, Vol 22 No 11

Main Articles

Psychological Challenges After Cancer: A Guide for Clinical Practice Reviewed in:

The Recklitis et al Article Reviewed

LATE EFFECTS CLINIC: Post-Trauma Symptoms in Cancer Survivors

Graft-Versus-Host Disease: A Complex Long-Term Side Effect of Hematopoietic Stem Cell Transplant Reviewed in:

The Barton-Burke et al Article Reviewed

DRUG ESSENTIALS: Small Molecule Multitargeted TKI Therapy

PATIENT INFORMATION: Fatigue in People with Cancer

Articles in this issue
The Recklitis et al Article Reviewed
A Challenge of Survivorship-Healing the Mind and Spirit
ONCOLOGY Nurse Edition October 2008, Vol 22 No 11
Addressing Psychological Challenges After Cancer: A Guide for Clinical Practice
Graft-Versus-Host Disease: A Complex Long-Term Side Effect of Hematopoietic Stem Cell
Post-Trauma Symptoms in Cancer Survivors
Small Molecule Multitargeted TKI Therapy
Commentary (Ezzone)-Graft-Versus-Host Disease: A Complex Long-Term Side Effect of Hematopoietic Stem Cell
La fatiga en personas con cáncer
Fatigue in People With Cancer
Recent Videos
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
2 experts in this video
2 experts in this video
Related Content
61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

Camila Ortega;Micah Brainerd;Christopher Mamone;Caroline Mangira;Andrew Fenton;Mary Murray
May 15th 2025
Article
A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

The safety profile of pembrolizumab in the KEYNOTE-B96 study was comparable with prior reports of the agent, and investigators observed no new safety signals.

Pembrolizumab Combo Extends PFS in Platinum-Resistant Ovarian Cancer

Russ Conroy
May 15th 2025
Article

Data from the KEYNOTE-B96 trial also show a significant overall survival improvement with pembrolizumab-based treatment in PD-L1–positive disease.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

Sheng Chow;Meredith Shamamian;Susan Laura Jao;Andreina Giron;Jessica Lin;Fardeen Bhimani;Eleni Kohilakis;Caroline Oska;Jana Fox;Sheldon Feldman;Maureen McEvoy
May 14th 2025
Article
With this decision, telisotuzumab vedotin is the first and only available therapy for this NSCLC subtype.

Telisotuzumab Vedotin Earns FDA Accelerated Approval in c-MET+ NSCLC

Russ Conroy
May 14th 2025
Article

Data from the phase 2 LUMINOSITY study support the FDA approval of telisotuzumab vedotin in this non–small cell lung cancer population.